A novel approach for establishing cardiovascular drug efficacy

被引：18
作者：
Heerspink, Hiddo. J. Lambers [1 ]
Grobbee, Diederick E. [2 ]
de Zeeuw, Dick [1 ]
机构：
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, NL-9713 AV Groningen, Netherlands
[2] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands
来源：
NATURE REVIEWS DRUG DISCOVERY | 2014年 / 13卷 / 12期
关键词：
INADEQUATE GLYCEMIC CONTROL; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; METFORMIN; THERAPY; TARGET; DAPAGLIFLOZIN; ALBUMINURIA; NEPHROPATHY; PROTECTION;
D O I：
10.1038/nrd4090-c2
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：942 / 944
页数：3
相关论文
共 16 条
  • [1] Effect of statin therapy on C-reactive protein levels - The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study
    Albert, MA
    Danielson, E
    Rifai, N
    Ridker, PM
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (01): : 64 - 70
  • [2] Phase II and Phase III attrition rates 2011-2012
    Arrowsmith, John
    Miller, Philip
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2013, 12 (08) : 568 - 568
  • [3] Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
    Bailey, Clifford J.
    Gross, Jorge L.
    Pieters, Anne
    Bastien, Arnaud
    List, James F.
    [J]. LANCET, 2010, 375 (9733) : 2223 - 2233
  • [4] De Jager J, 2005, J INTERN MED, V257, P100
  • [5] Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy
    de Zeeuw, D
    Remuzzi, G
    Parving, HH
    Keane, WF
    Zhang, ZX
    Shahinfar, S
    Snapinn, S
    Cooper, ME
    Mitch, WE
    Brenner, BM
    [J]. CIRCULATION, 2004, 110 (08) : 921 - 927
  • [6] Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy:: Post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial
    Eijkelkamp, Wouter B. A.
    Zhang, Zhongxin
    Remuzzi, Giuseppe
    Parving, Hans-Henrik
    Cooper, Mark E.
    Keane, William F.
    Shahinfar, Shahnaz
    Gleim, Gilbert W.
    Weir, Matthew R.
    Brenner, Barry M.
    de Zeeuw, Dick
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 18 (05): : 1540 - 1546
  • [7] The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: Results from the ONTARGET trial
    Heerspink, Hiddo J. Lambers
    Gao, Peggy
    de Zeeuw, Dick
    Clase, Catherine
    Dagenais, Gilles R.
    Sleight, Peter
    Lonn, Eva
    Teo, Koon T.
    Yusuf, Salim
    Mann, Johannes F.
    [J]. EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2014, 21 (03) : 299 - 309
  • [8] Hou F. F., J AM SOC NEPHROL, V18
  • [9] Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease
    Jafar, TH
    Stark, PC
    Schmid, CH
    Landa, M
    Maschio, G
    Marcantoni, C
    de Jong, PE
    de Zeeuw, D
    Shahinfar, S
    Ruggenenti, P
    Remuzzi, G
    Levey, AS
    [J]. KIDNEY INTERNATIONAL, 2001, 60 (03) : 1131 - 1140
  • [10] Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial
    Miao, Y.
    Dobre, D.
    Lambers Heerspink, H. J.
    Brenner, B. M.
    Cooper, M. E.
    Parving, H-H.
    Shahinfar, S.
    Grobbee, D.
    de Zeeuw, D.
    [J]. DIABETOLOGIA, 2011, 54 (01) : 44 - 50
12